Quarterly report pursuant to Section 13 or 15(d)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Research and Development (Policies)

v3.20.2
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Research and Development (Policies)
6 Months Ended
Jun. 30, 2020
Policies  
Research and Development Research and Development

 

Research and development costs are expensed as incurred. The majority of the Company's research and development costs consist of clinical study expenses. These consist of fees, charges, and related expenses incurred in the conduct of clinical studies conducted with Company products by independent outside contractors. External clinical studies expenses were approximately $2,013,000 and $1,314,000 for the six months ended June 30, 2020 and 2019, respectively.